Cargando…

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users

Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Jui-Ting, Hsu, Ping-I, Shie, Chang-Bih, Chuah, Seng-Kee, Wu, I-Ting, Huang, Wen-Wei, Tang, Sheng-Yeh, Tsai, Kun-Feng, Kuo, Li-Fu, Ghose, Supratip, Hsu, Jui-Che, Shih, Chih-An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950806/ https://www.ncbi.nlm.nih.gov/pubmed/35334612 http://dx.doi.org/10.3390/medicina58030436

Ejemplares similares

Update on the second-line treatment of Helicobacter pylori infection: a narrative review
por: Shih, Chih-An, et al.
Publicado: (2023)

Application of artificial intelligence in endoscopic image analysis for the diagnosis of a gastric cancer pathogen-Helicobacter pylori infection
por: Lin, Chih-Hsueh, et al.
Publicado: (2023)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
por: Poizot-Martin, Isabelle, et al.
Publicado: (2015)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study
por: Elfiky, Abdo A., et al.
Publicado: (2016)

Computational modeling of the p7 monomer from HCV and its interaction with small molecule drugs
por: Wang, Yi-Ting, et al.
Publicado: (2013)

Repurposing old drugs as antiviral agents for coronaviruses
por: Yang, Cheng-Wei, et al.
Publicado: (2020)

Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs
por: Liang, Chih-Ming, et al.
Publicado: (2019)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Theoretical Analysis of Fe K-Edge XANES on Iron Pentacarbonyl
por: Chen, Wei-Ting, et al.
Publicado: (2020)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
por: Riaz, Hafiza Arooba, et al.
Publicado: (2023)

High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan
por: Kuo, Irene, et al.
Publicado: (2006)

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
por: Kuo, Meng-Hsuan, et al.
Publicado: (2020)

A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

New Insights in Recurrent HCV Infection after Liver Transplantation
por: Hsu, Shih-Hsien, et al.
Publicado: (2013)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
por: Flynn, Jacqueline K, et al.
Publicado: (2014)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China
por: Tao, Jun, et al.
Publicado: (2015)

Difference between Female and Male Patients with Oral Squamous Cell Carcinoma: A Single-Center Retrospective Study in Taiwan
por: Lin, Nan-Chin, et al.
Publicado: (2020)

Survival and clinicopathological characteristics of different histological grades of oral cavity squamous cell carcinoma: A single-center retrospective study
por: Lin, Nan-Chin, et al.
Publicado: (2020)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Analysis of drug abuse data reported by medical institutions in Taiwan from 2002 to 2011
por: Hsu, Jui, et al.
Publicado: (2014)

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
por: Chayama, Kazuaki, et al.
Publicado: (2015)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
por: Messina, Vincenzo, et al.
Publicado: (2020)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

Electrospun, Resorbable, Drug-Eluting, Nanofibrous Membranes Promote Healing of Allograft Tendons
por: Weng, Chun-Jui, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Detection of Potential Drug-Drug Interactions for Outpatients across Hospitals
por: Yeh, Yu-Ting, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bi28e2ee05f6pakgeklq7qcuqk